Compared with the model group, the mRNA and protein expression levels of β-catenin, c-Myc, and cyclin D1 were significantly reduced after TSC drug intervention, whereas the mRNA and protein expression levels of the negative regulatory protein SFRP4 of the Wnt pathway were significantly increased. The gene discussed is CCND1; the disease is tuberous sclerosis.